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Understanding the regulation of islet cell mass has
important implications for the discovery of regenera-
tive therapies for diabetes. The liver plays a central
role in metabolism and the regulation of endocrine
cell number, but liver-derived factors that regulate
a-cell and b-cell mass remain unidentified. We pro-
pose a nutrient-sensing circuit between liver and
pancreas in which glucagon-dependent control of
hepatic amino acid metabolism regulates a-cell
mass. We found that glucagon receptor inhibition
reduced hepatic amino acid catabolism, increased
serum amino acids, and induced a-cell proliferation
in an mTOR-dependent manner. In addition, mTOR
inhibition blocked amino-acid-dependent a-cell
replication ex vivo and enabled conversion of a-cells
into b-like cells in vivo. Serum amino acids and a-cell
proliferation were increased in neonatal mice but fell
throughout postnatal development in a glucagon-
dependent manner. These data reveal that amino
acids act as sensors of glucagon signaling and
can function as growth factors that increase a-cell
proliferation.
INTRODUCTION
The major endocrine cell types in the pancreatic islets—a-cells
and b-cells, which secrete glucagon and insulin, respectively—
are essential for glucose homeostasis. In addition to loss of
b-cells (Prentki and Nolan, 2006; Matveyenko and Butler,
2008), inappropriately elevated postprandial glucagon levels
are a hallmark of type 2 diabetes (Reaven et al., 1987; D’Alessio,
2011). Activation of the glucagon receptor (GCGR) drives hepaticglucose output, which contributes significantly to hyperglycemia
in diabetes (Unger and Cherrington, 2012). As a result, inhibition
of GCGR is a therapeutic strategy for the treatment of diabetes,
and a number of agents that block glucagon action have entered
clinical trials (Bagger et al., 2011).
In addition to secreting glucagon, a-cells can serve as a
source of regenerating b-cells in diabetic mice. After b-cell abla-
tion, a-cells can transdifferentiate into b-cells and reverse dia-
betes in mice (Thorel et al., 2010; Chung et al., 2010), raising
the possibility that b-cell regeneration through a-cell transdiffer-
entiation could be a novel mechanism for the treatment of dia-
betes. However, the mechanisms that regulate a-cell mass and
their conversion into b-cells remain unknown. Both a-cells and
b-cells arise fromNgn3-expressing precursors during embryonic
development, and the differential expression of transcription
factors Arx1 and Pax4 defines a-cell and b-cell fate (Collombat
et al., 2007, 2009). These cells continue to expand and mature
after birth (Bonner-Weir, 2000; Vuguin et al., 2006). Significantly,
forced expression of Pax4 in a-cells drives their conversion into
b-cells and reverses diabetes (Al-Hasani et al., 2013).
Most of our understanding of the regulation of a-cell mass has
come from studies in GCGR knockout (Gcgr/) mice (Gelling
et al., 2003), glucagon knockout (Gcg/) mice (Hayashi et al.,
2009), and PC2 knockout mice (Webb et al., 2002), which have
revealed the existence of a circuit in which the loss of glucagon
signaling triggers a-cell hyperplasia. GCGR antagonists also
cause a-cell hyperplasia (Sloop et al., 2004; Gu et al., 2009).
Furthermore, a-cell hyperplasia has also been reported in
humans with inactivating mutations in GCGR (Yu, 2014). The
molecular nature of this glucagon-dependent circuit and the
mechanisms governing its activity remain unknown. However,
liver-specific loss of GCGR (Longuet et al., 2013) promotes
a-cell hyperplasia, indicating that the liver is the source of the
signal that activates the circuit. In addition, Longuet et al.
demonstrated that this signal is a secreted factor, but the identity
of the factor remains unknown.Cell Reports 12, 495–510, July 21, 2015 ª2015 The Authors 495
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Figure 1. GCGR Antagonist Antibodies Improve Glucose Homeostasis and Increase a-Cell Number
(A) Fed blood glucose (top) and glucose tolerance on day 8 (bottom) in ZDF rats treated with anti-GCGR (5 mg/kg). Data are mean ± SEM; n = 7. *p < 0.01,
compared to control animals at each time point. veh, vehicle.
(legend continued on next page)
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Here, we report that glucagon-dependent regulation of he-
patic amino acid catabolism is coupled to a-cell mass. In the
absence of glucagon signaling, hepatic expression of amino
acid catabolism enzymes was reduced, and amino acids
accumulated in the serum and correlated with activation of the
mammalian Target of Rapamycin (mTOR), a central regulator
of cell growth and proliferation in response to amino acids
(Laplante and Sabatini, 2012), in a-cells. Rapamycin, an mTOR
inhibitor, blocked a-cell hyperplasia in mice treated with a
GCGR antagonist and amino-acid-induced a-cell proliferation
in isolated islets ex vivo. In addition, serum amino acids corre-
lated with a-cell mTOR activity and proliferation during postnatal
islet maturation. Furthermore, the fate of a-cells in Gcgr/ mice
was dependent on mTOR activity, as treatment of Gcgr/ mice
with rapamycin induced a-cells to apoptose or, remarkably, to
transdifferentiate into insulin-expressing b-like cells. Our data
show that, by acting as sensors of glucagon action and as
growth factors, amino acids relay the degree of hepatic glucagon
signaling to islets and establish a-cell mass through activation of
the mTOR pathway.
RESULTS
GCGR Antagonists Improve Glucose Homeostasis and
Increase a-Cell Number
Recently, we described the structural basis of human GCGR in-
hibition by monoclonal antibodies (mAbs) (Koth et al., 2012; Mu-
kund et al., 2013), which bind exclusively to GCGR (Figure S1A).
To determine whether these antibodies, which inhibit GCGR by
distinct molecular mechanisms, could improve glucose homeo-
stasis, we tested them in diabetic rodents. Administration of
mAb23, an inverse agonist, to Zucker Diabetic Fatty (ZDF) rats
or streptozotocin (Stz)-induced diabetic rats reduced blood
glucose and improved glucose tolerance in both models of dia-
betes (Figures 1A and 1B). Similarly, mAb7, an allosteric antag-
onist, reduced blood glucose and improved glucose tolerance
in db/dbmice (Figure 1C), with similar effects in Stz-induced dia-
betic mice after long-term administration (Figures S1B and S1C).
Neither antibody induced hypoglycemia (Figures 1A–1C and
S1B) or affected body weight (Figures S1D–S1G). Both mAb23
and mAb7 increased serum glucagon levels (Figures S1H and
S1I), as expected from previous studies (Sloop et al., 2004; Gu
et al., 2009). These data establish that these antibodies may
serve as effective therapeutics to reduce blood glucose in dia-
betic patients through the inhibition of glucagon signaling.
As mAb23 and mAb7 have similar effects in vivo, we focused
on mAb7, hereinafter referred to as anti-GCGR, in further(B) Fed blood glucose (top) 14 days after treatment with anti-GCGR (5 mg/kg, on
induced diabetic rats. Data are mean ± SEM, n = 4. IgG, immunoglobulin G. *p <
(C) Fed blood glucose (top) and glucose tolerance on day 14 (bottom) in db/dbmic
n = 6. *p < 0.01, compared to control animals at each time point.
(D) Islet density in pancreatic sections of Gcgr/ mice (top) and db/dbmice treat
n = 4–6. *p < 0.01.
(E) Representative images of islets from C57B6 and db/db mice treated with ant
(F and G) Quantification of a-cell area/islet (F, left) and b-cell area/islet (F, right) an
treated with anti-GCGR (5mg/kg, qw) for 14 or 28 days, respectively. Wt, wild-typ
ns, not significant.studies. Anti-GCGR promoted changes in islet number and
cellular composition (Figure 1). Consistent with an increase in
islet number in Gcgr/ mice, anti-GCGR increased the number
of islets in the pancreas of db/dbmice after 4 weeks of treatment
(Figure 1D; Figure S2). In addition, anti-GCGR also increased
a-cell number per islet 4-fold in lean mice after 10 days and
8-fold in db/db mice after 4 weeks of treatment (Figures 1E
and 1F), similar to other GCGR antagonists (Sloop et al., 2004;
Gu et al., 2009). Anti-GCGR does not affect b-cell number under
these short-term treatment conditions (Figure 1F), although we
did find an increase in the number of a rare population of cells
co-expressing glucagon and insulin in islets of both wild-type
and db/db mice treated with anti-GCGR (Figure 1G). Similar bi-
hormonal cells have been described in Gcgr/ mice (Vuguin
et al., 2006), as well as in diabetic mice in which transdifferentia-
tion of a-cells into b-cells promoted b-cell regeneration (Thorel
et al., 2010; Chung et al., 2010).
Glucagon Regulates Hepatic Amino Acid Metabolism
We set out to identify the pathways and mechanisms that regu-
late a-cell and bi-hormonal cell number. A number of studies
(Sloop et al., 2004; Chen et al., 2005)—the most recent of which
described an increase in a-cells in mice with liver-specific loss of
GCGR (Longuet et al., 2013)—demonstrated that the liver may
be the source of circulating factors that promote a-cell hyperpla-
sia. In an effort to identify liver-expressed secreted factors that
could act as growth factors in a-cell hyperplasia, we performed
gene expression analyses of livers fromGcgr/mice (Figure 2A)
and anti-GCGR-treated db/db mice (Figure 2B). Even though
these are not liver-specific tools, we reasoned that, as a-cells
increase in both of these conditions, the responsible factors
should be increased in the livers under both conditions. Notably,
among the genes that are common to both conditions, we
identified only two secreted proteins with increased expression
(Figures 2A and 2B). However, the expression of both of these
genes, InhbA and DefB1, was also increased by glucagon in pri-
mary hepatocytes (Figure S3), indicating that they were not
increased in vivo due to specific loss of glucagon signaling and
were, therefore, unlikely to be responsible for a-cell hyperplasia.
Next, using gene set enrichment analysis (GSEA), we found
two gene sets, which were populated with genes involved in
amino acid metabolism, that were significantly downregulated
in both Gcgr/ mice (Figure 2A) and anti-GCGR-treated db/db
mice (Figure 2B). In order to identify the individual genes that
are common to both conditions, we performed a four-way anal-
ysis of the differentially expressed genes in the livers of these
mice and found that many of the downregulated genes in bothe dose every 2 weeks [q2w]) and glucose tolerance on day 19 (bottom) in Stz-
0.01, compared to control animals at each time point.
e treatedwith anti-GCGR (5mg/kg, weekly dosing [qw]). Data aremean ±SEM,
ed with anti-GCGR for 4 weeks (5 mg/kg, qw) (bottom). Data are mean ± SEM,
i-GCGR (5 mg/kg, qw) for 14 or 28 days, respectively. Scale bars, 50 mm.
d of bi-hormonal (glucagon/insulin) cell area/islet (G), in C57B6 and db/dbmice
e. 14–66 islets were counted per mouse. Data are mean ± SEM, n = 6. *p < 0.01;
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Figure 2. Comparison between Gcgr/ Mice and Anti-GCGR-Treated Mice Identifies Amino Acid Metabolism Genes
(A) Volcano plot of microarray data from livers of Gcgr/ mice, compared to Gcgr+/+ mice (top), and probability plot (Q-Q plot) depicting GSEA of these data
(bottom). Data are from n = 5–6 mice per group.
(B) Volcano plot of microarray data from livers of db/db mice treated with anti-GCGR (5 mg/kg, qw for 4 weeks) (top) and probability plot (Q-Q plot) depicting
GSEA of these data (bottom). Data are from n = 5–6 mice per group.
(C) Four-way plot of microarray analyses displaying differentially expressed genes in the livers of Gcgr/ mice (x axis) and db/db mice treated with anti-GCGR
(y axis), compared to their respective controls. Blue dots represent genes regulated in both Gcgr/ and anti-GCGR-treated mice; adjusted p < 0.05. Red and
green dots represent genes regulated in either Gcgr–/– or anti-GCGR-treated mice, respectively; adjusted p value < 0.05. Data are from n = 5–6 mice per group.
(D) mRNA levels (qPCR) of 106 transcripts encoding amino acid metabolism proteins from livers of db/dbmice treated with anti-GCGR (5mg/kg, qw for 4 weeks).
Data are fold change compared to untreated db/db mice. Red and green shaded areas represent transcripts with 2-fold change; p% 0.05.
(E) mRNA levels (Quantigene) of urea cycle genes in C57B6 mice treated with anti-GCGR (10 mg/ml) for 10 days. Data are mean ± SEM; n = 12. *p% 0.05. Wt,
wild-type.
(F) mRNA levels (Quantigene) in primary human hepatocytes treatedwith glucagon (50 nM) for 2 hr, with or without (+ or) anti-GCGR (20 mg/ml). Data aremean ±
SEM; n = 3 independent experiments. *p% 0.05.conditions encoded proteins involved in amino acid catabolism
(Figure 2C). Using a panel of real-time PCR primers specific for
amino acid metabolism genes, we found that approximately498 Cell Reports 12, 495–510, July 21, 2015 ª2015 The Authors50%of these genes displayed decreased expression in the livers
of anti-GCGR-treated db/db mice (Figure 2D). These included
genes such as the serine dehydratases, Sds and Sdsl, aspartate
aminotransferase (Got1), glutaminase (Gls2), cystathionase (Cth),
and tyrosine aminotransferase (Tat), all of which generate
ammonia as part of the catabolism of a number of amino acids.
In addition, ornithine aminotransferase (Oat), which regulates
ornithine levels, the key intermediate in the urea cycle, and the
urea cycle enzymes carbamoyl-phosphate synthase (Cps1)
and argininosuccinate synthase (Ass1) were also reduced.
Notably, a number of genes involved in secondary amino acid
metabolism were increased upon GCGR inhibition in db/db
mice (Figures 2D). In order to demonstrate that the glucagon
dependence of amino acid catabolism was not restricted to
diabetic mice treated with anti-GCGR, we measured the levels
of mRNAs for all the urea cycle enzymes in the livers from wild-
type mice and found that a single dose of anti-GCGR reduced
the mRNA levels of all of these enzymes but not that of
another ornithine metabolism enzyme, ornithine transcarbamy-
lase (Otc1) (Figure 2E). Finally, we determined whether the genes
downregulated by anti-GCGR in vivo were glucagon target
genes in primary hepatocytes in vitro. We found that the genes
encoding amino acid catabolism enzymes, urea cycle enzymes,
and the mitochondrial ornithine transporter Slc25A15, were acti-
vated by glucagon after 2 hr in primary hepatocytes (Figures 2F
and S3A), and, similar to its effects in vivo, anti-GCGR blocked
glucagon activation of these genes in vitro (Figure 2F).
GCGR Inhibition Increases Serum Amino Acid Levels
Next, we tested whether amino acids accumulated in the serum
in the absence of hepatic amino acid catabolism. If so, this
would raise the intriguing possibility that amino acids may be
the factors that promote a-cell hyperplasia in Gcgr/ and anti-
GCGR-treated mice. First, using metabolomic profiling of over
250 soluble metabolites in the livers and sera of Gcgr/ mice,
we found that, of the 50 significantly (p% 0.05) changed metab-
olites in serum, 22 overlapped with liver metabolites; 19 of these
22 were amino acids (Figure 3A). In addition to nearly all of the
20 proteinogenic amino acids, amino acids of the urea cycle
such as citrulline and ornithine and many amino acid derivatives
were elevated in both the livers and sera of Gcgr/ mice
compared to Gcgr+/+ mice (Figures 3B and S3B). A single dose
of anti-GCGR increased serum amino acid levels in wild-type
mice and rats (Figures 3C and 3D). This acute effect was main-
tained as long as antibody was in the serum (Figure 3E). The
rapid peak of serum amino acid levels after antibody dosing
followed by time- and antibody-dependent decline indicated
a direct relationship between anti-GCGR inhibition of hepatic
glucagon signaling and serum amino acid levels. This is in
contrast to the increase in serum glucagon levels, which
continue to rise even as anti-GCGR concentrations decline
(Figure 3E) and likely reflects a-cell hyperplasia in addition to
increased glucagon secretion. The increase in glucagon secre-
tion within hours of anti-GCGR administration is likely secondary
to the acute increase in serum amino acids, many of which are
known to promote glucagon secretion (Eisenstein and Strack,
1978). Next, we tested the effect of increased protein consump-
tion on serum amino acid levels in anti-GCGR treated mice. We
found that anti-GCGR led to a greater increase in amino acids in
mice on a high-protein diet compared to the increase in mice on
a low-protein diet (Figure S3C), suggesting that amino acid accu-mulation upon anti-GCGR treatment was due to inhibition of
hepatic amino acid clearance.
In order to test the hypothesis that hepatic amino acid catab-
olism regulates a-cell mass, we expressed GCGR in the livers
of Gcgr/ mice using adenovirus (Figures S3D and S3E). As
expected, the expression of mRNAs encoding the amino acid
catabolism genes that were reduced in Gcgr/ mice (Figure 2)
increased upon GCGR expression (Figure 3F), along with a
concomitant normalization of serum amino acid levels (Fig-
ure 3G). Serum glucagon levels were also reduced (Figure 3H),
and, strikingly, the number of a-cells in these mice was reduced
by 50%, without any effect on b-cell number (Figure 3I). The
reversal of the Gcgr/ phenotype by liver-specific expression
of GCGR suggests that amino acids could be factors responsible
for the hyperplasia in Gcgr/ and anti-GCGR-treated mice.
a-Cell Proliferation Correlates with Serum Amino Acid
Levels in Neonatal Mice
Our strategy for identifying the factor(s) promoting a-cell hyper-
plasia is based on the hypothesis that any such factors are regu-
lated in a similarmanner under all conditions inwhich a-cell mass
expands. In order to test this hypothesis in a physiological, non-
genetically or pharmacologically perturbed situation, we studied
a-cell mass in the post-natal period, when islet cell numbers
increase due to endogenous cues (Bonner-Weir, 2000; Vuguin
et al., 2006). We quantified a-cells in Gcgr+/+ and Gcgr/ mice
from postnatal day (P) 2.5 to 3 months of age. In Gcgr+/+ mice,
a-cell mass expanded 50-fold from birth to peak at P19 (Fig-
ure 4A), along with a 2.5-fold increase in the a-cell area per islet
(Figure 4B). Incorporation of 5-ethynyl-20-deoxyuridine (EdU) re-
vealed robust proliferation of a-cells in the early postnatal period
(Figure 4C). Notably, a-cell mass was the same in Gcgr+/+ and
Gcgr/ mice 1 week after birth and only marginally different
by 3 weeks of age (Figures 4A and 4B). In addition, there
was no difference in proliferation of a-cells in Gcgr+/+ and
Gcgr/ mice up to P7.5, after which time, proliferation stops
in Gcgr+/+ mice (Figure 4C). However, proliferation continued
in Gcgr/ mice at P19 (Figure 4C). Notably, a-cell mass and
a-cell area per islet decreased almost 4-fold after P19 in
Gcgr+/+ mice (Figures 4A and 4B). However, this did not occur
in Gcgr/ mice. Instead, a-cell mass and a-cell area per islet
continued to increase inGcgr/mice, likely due to the combina-
tion of the failure to stop proliferating before weaning and the
pruning of a-cells after weaning (Figures 4A–4C). These data
demonstrate that glucagon signaling is required during the late
postnatal period for establishing a-cell mass in adult mice.
Next, we obtained gene expression profiles of livers from
neonatalGcgr+/+ andGcgr/mice.While there was a significant
number of differentially expressed genes in the livers of these
mice throughout the neonatal period (Figures S4A–S4D), surpris-
ingly, there were no differences in the liver expression of amino
acid catabolism or urea cycle genes between Gcgr+/+ and
Gcgr/ mice in the early postnatal period (Figure 4D). This
was primarily due to the very low levels of expression of these
genes before P7.5, which, in turn, were not due to a lack of circu-
lating glucagon (Figure 4E) or hepaticGcgr expression inGcgr+/+
mice (Figures 4F and 4G). The expression ofmany of these genes
was detectable at P7.5 and P19 in Gcgr+/+ mice but wasCell Reports 12, 495–510, July 21, 2015 ª2015 The Authors 499
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Figure 3. Serum Amino Acid Levels Correlate with Gcgr Activity and a-Cell Number
(A) Characterization of metabolites from Gcgr/ and Gcgr+/+ mice displaying statistically significant differences (p % 0.05) in both liver and serum. n = 6
per group.
(legend continued on next page)
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significantly lower than in 3-month-old mice (Figure 4D) and re-
mained low or absent throughout postnatal development in
Gcgr/ mice (Figure 4D). In addition, we found that there was
no difference in blood glucose levels between Gcgr+/+ and
Gcgr/ mice at P1.5 (Figure S4E) or P2.5 (Figure 4H). Overall,
these data indicated that glucagon does not regulate hepatic
amino acid catabolism or gluconeogenic gene expression in
the early postnatal period inGcgr+/+ mice and that blood glucose
levels are independent of glucagon signaling at least up to P7.5.
Next, we measured serum amino acid levels throughout the
postnatal period and found that nearly all proteinogenic amino
acids and ornithine were high in serum of neonatal Gcgr+/+
mice, relative to 3-month-old mice, and, consistent with the
gene expression data, there were no differences in amino acid
levels in neonatal Gcgr+/+ and Gcgr/ mice at P2.5 (Figure 4I).
Furthermore, we found that amino acid levels fell throughout
postnatal development in Gcgr+/+ mice. In contrast, in Gcgr/
mice, amino acids levels continued to rise throughout the post-
natal period and, for some amino acids, continued to rise
throughout the 3-month period of this study (Figure 4I). These
data further demonstrate the relationship between hepatic
glucagon signaling, serum amino acids, and a-cell mass and
further suggested that amino acids could be factors responsible
for establishing a-cell mass.
Amino Acids Promote a-Cell Proliferation
As a-cell proliferation during the postnatal period correlated with
serum amino acids, we reasoned that the observed increase in
a-cell mass upon inhibition of GCGR with anti-GCGR (Figure 1F)
may also be due to a-cell proliferation. To test this, we engi-
neered a transgenic mouse, GcgCreERT2;tdTomato, which en-
ables lineage tracing of fluorescent a-cells in situ. In this mouse,
tamoxifen-inducible Cre recombinase (CreERT2) was placed
under the control of the entire 50 regulatory region of the mouse
glucagon gene in a bacterial artificial chromosome (BAC) (Fig-
ure S5A) and expressed as a transgene in mice containing a
floxed allele of the fluorescent protein tdTomato. Tamoxifen
induced specific tdTomato labeling of a-cells in this mouse (Fig-
ure 5B; Figure S5B). In order to determine whether anti-GCGR
induced replication of a-cells, we labeled a-cells with tdTomato
followed by a tamoxifen washout period of 2 weeks before
administration of anti-GCGR (Figure 5A). Anti-GCGR increased
the number of tdTomato-positive cells, demonstrating expan-
sion of the a-cell pool from pre-existing tdTomato-labeled
a-cells (Figures 5B and S5C). We also evaluated the expression
of ki67, a marker of active cell proliferation, in islets during anti-
body treatment. We detected ki67 in as many as 5%–10% of the
a-cells in anti-GCGR-treated mice, while ki67 was undetectable
in islets from mice treated with a control antibody (Figures 5C(B) Quantification of amino acids displaying significantly different levels in the se
(C) Quantification of amino acids in sera of C57B6 mice 10 days after a single do
(D and E) Time course of changes of selected amino acids (D), glucagon (E, left),
GCGR (10 mg/kg). Data are mean ± SEM; n = 4. *p% 0.05 for each time point c
(F) mRNA levels of glucagon target genes inGcgr/mice after re-expression of G
Gcgr/ mice. Data are mean ± SEM; n = 5–6 per group. *p% 0.05.
(G–I) Serum amino acids (G) and serum glucagon levels (H) in Gcgr/ mice be
postdose.(I) a-cell and b-cell area/islet in Gcgr/ mice 9 days after administratioand 5D). In addition, we found that anti-GCGR did not increase
tdTomato-positive a-cells in a tamoxifen-inducibleNgn3-lineage
reporter mouse, which tracks endocrine cell precursors (Gu
et al., 2002) (Figure S5D). These data demonstrate that anti-
GCGR promoted a-cell hyperplasia through replication of a-cells
and without any measurable contribution from Ngn3-positive
endocrine cell precursors.
In order to determine whether high amino acid concentrations
were sufficient to promote a-cell replication, we developed a
pulse-chase assay to quantify fluorescent a-cells in isolated
islets. Purified islets from the GcgCreERT2;tdTomato mouse
were incubated with 4-OH tamoxifen ex vivo for 24 hr in order
to fluorescently label the a-cells with tdTomato (Figures 5E and
5F). These islets were then cultured inmedia containing an amino
acid cocktail (Table S1) that matched the serum amino acid con-
centrations ofGcgr+/+ (low amino acids) andGcgr/ (high amino
acids) mice for 7 days, after which fluorescent a-cells were quan-
tified by fluorescence-activated cell sorting (FACS). High amino
acids stimulated a 2- to 3-fold increase in a-cells in this ex vivo
setting (Figure 5G),whichmatched the increase thatwecanmea-
sure by this FACS method when a-cells proliferated in vivo for
10 days after anti-GCGR treatment (Figure S5C). Thesedata sup-
port the hypothesis that anti-GCGR-induced a-cell hyperplasia
in adult mice is due to a-cell replication driven by the increase
in serum amino acid levels after anti-GCGR treatment.
mTOR Activation Is Required for a-Cell Hyperplasia
To determine the mechanism of anti-GCGR induced a-cell pro-
liferation, we tested whether mTOR was active in a-cells under
conditions of increased amino acids. First, immunostaining for
pS6, a downstream target of mTOR signaling (Hay and Sonen-
berg, 2004), demonstrated that the mTOR pathway was active
in a-cells and b-cells of neonatal mice at P7.5 (Figure 6A). Islets
from P19 Gcgr+/+ mice were pS6 negative, while pS6 was still
detectable in a-cells of Gcgr/ mice at P19 (Figure 6A). These
data correlated with the reduction in the serum levels of most
amino acids in Gcgr+/+ mice, but not in Gcgr/ mice (Figure 4I),
and the lack of a-cell proliferation in Gcgr+/+ mice but continued
a-cell proliferation in Gcgr/ mice at P19 (Figure 4C). Next, we
found that anti-GCGR treatment also activated pS6 in a-cells
(Figure 6B). To determine whether this activation of mTOR in
a-cells was required for a-cell proliferation, we co-treated mice
with anti-GCGR and the mTOR inhibitor rapamycin. We found
that rapamycin prevented both the anti-GCGR induction of
pS6 in a-cells (Figure 6B) and the increase in a-cell number (Fig-
ure 6C), aswell as the increase in serumglucagon levels normally
seen in anti-GCGR-treated mice (Figure 6D). Rapamycin did
not block anti-GCGR-induced increase in serum amino acids
(Figure 6E).ra (p% 0.01) of Gcgr+/+ and Gcgr/ mice. Data are mean ± SEM; n = 6.
se of anti-GCGR (5 mg/kg). Data are mean ± SEM; n = 6. *p% 0.05.
and anti-GCGR (E, right) in non-diabetic rats treated with a single dose of anti-
ompared to baseline.
CGR in the liver using adenovirus (Ad)-GCGR, compared to Ad-EGFP-infected
fore and 9 days after re-expression of GCGR in the liver. Pre, predose; Post,
n of Ad-GCGR. In (G)–(I), data are mean ± SEM; n = 3–5 per group. *p% 0.01.
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Next, we tested the requirement for mTOR activation in amino-
acid-stimulated a-cell proliferation ex vivo. High, but not low,
amino acids induced pS6 staining in a-cells (Figure 6F), but not
in b-cells (Figure S6A), in mouse islets cultured for 7 days. In
addition, high, but not low, amino acids induced EdU incorpora-
tion into a-cells over 7 days in culture, demonstrating that
high amino acids were sufficient to induce a-cell proliferation
ex vivo (Figures 6G and 6H). We found that pS6 staining and
EdU were rarely coincident, but we did find that mTOR inhibition
by rapamycin prevented both high-amino-acid-induced pS6
activation and EdU incorporation into a-cells (Figures 6F–6H).
Rapamycin-dependent, high-amino-acid-induced mTOR acti-
vation was also detected in a-cells in human islets (Figure S6B).
Notably, glucagon staining was weak in many pS6-positive cells;
in some cells, it was even undetectable. Collectively, these data
suggest that a-cell proliferation is dependent on mTOR activa-
tion and that cells may lose glucagon expression and/or content
coincident with mTOR activation and proliferation, at least
ex vivo. Overall, these data demonstrate that a-cells sense
amino acids in vivo and in vitro and further suggest that amino
acids promote a-cell replication in anti-GCGR-treated mice.
Rapamycin Reverses a-Cell Hyperplasia inGcgr/Mice
Phospho-S6 (pS6) staining was readily detectable in the a-cells
of 3-month-old Gcgr/ mice (Figure 7A), indicating that these
a-cells still respond to amino acids. However, pS6 staining
was absent from a-cells in Gcgr/ mice infected with Ad-
GCGR (Figure 7A), supporting the conclusion that re-expression
of GGCR in the livers ofGcgr/mice reduced the a-cell number
due to a reduction in serum amino acids (Figures 3G and 3I). Pro-
liferation was difficult to detect in the a-cells of 3-month-old
Gcgr/mice (Figure 4C), suggesting that not only is mTOR acti-
vation required for amino-acid-dependent a-cell proliferation
(Figure 6), but it may also play a role in the maintenance of these
a-cells in adult Gcgr/ mice. To test this, we treated Gcgr/
mice with rapamycin. After 12 days, pS6 staining was undetect-
able in a-cells (Figure 7A). Furthermore, a-cell hyperplasia and
hyperglucagonemia were reversed in these mice (Figures 7B
and 7C), but without a reduction in serum amino acid levels (Fig-
ure S7A). In order to determine the fate of these a-cells, we pre-
labeled a-cells inGcgCreERT2;tdTomatomice crossed onto the
Gcgr/ background with tdTomato using tamoxifen. We found
that the majority of the tdTomato-positive a-cells were lost from
the islets after 12 days of rapamycin treatment (Figures 7D).
Staining for activated caspase3 revealed that rapamycin treat-
ment induced apoptosis of these cells. Two days after a single
dose of rapamycin, caspase3 was localized in the heterochro-
matin of a number of a-cells, characteristic of early apoptosis.Figure 4. Postnatal a-Cell Proliferation Correlates with Gcgr-Depende
(A–C) a-cell mass (A), a-cell area/islet (B), and the percentage of EdU-positive a-ce
ranged from 45 to >1,000. In (C), average number of a-cells counted per group w
(D) mRNA levels of glucagon target genes in neonatal Gcgr+/+ and Gcgr/ mice
(E) Serum glucagon levels in neonatal Gcgr+/+ mice. Data are mean ± SEM; n = 6
(F) GCGR mRNA level in prenatal and postnatal livers from Gcgr+/+ mice. Data a
(G) Western blot of GCGR in membranes extracted from livers of neonatal Gcgr+
(H) Blood glucose levels in neonatal Gcgr/ and Gcgr+/+ mice. Data are mean ±
(I) Serum levels of selected amino acids in neonatal Gcgr+/+ and Gcgr/ mice. DAfter 5 days, caspase3-positive a-cells in later stages of cell
death could be detected (Figure 7E). Activated caspase3 was
undetectable above background in the a-cells or b-cells of
control Gcgr/ mice and by day 12 in treated mice, even with
ongoing rapamycin dosing (Figure S7B). These data are consis-
tent with the observation that not all a-cells in islets from un-
treated Gcgr/ mice are pS6 positive and that the remaining
a-cells after rapamycin treatment are pS6 negative (Figure 7A).
Remarkably, we found that a significant number of the remain-
ing tdTomato-positive a-cells appeared to have transdifferenti-
ated into b-like cells, as they were no longer glucagon positive
but were now insulin positive (Figure 7D). These cells also ex-
pressed b-cell markers, including Nkx6.1, Glut2, C-peptide,
and Pdx1 (Figures 7F and S7C). These data indicated not only
that mTOR activity was required to maintain the high number
of a-cells in the Gcgr/ mice but also that mTOR activity in
a-cells prevented transdifferentiation of a-cells into b-like cells.
DISCUSSION
The existence of a circuit that compensates for the loss of
hepatic glucagon signaling by triggering an increase in the num-
ber of a-cells in the pancreatic islet has been well documented
(Gelling et al., 2003; Longuet et al., 2013; Yu, 2014). However,
the molecular nature of this circuit has remained elusive. There
is good evidence that the liver is the primary source of the signal
that promotes a-cell hyperplasia. For example, loss of hepatic
GCGR is sufficient to activate the circuit, and a-cells isolated
from Gcgr+/+ mice proliferated when transplanted into liver-spe-
cificGcgr/mice (Longuet et al., 2013), demonstrating a critical
role for a soluble factor. Although a secreted protein would be a
likely candidate, we did not identify any glucagon-regulated
secreted proteins in the gene expression profiles of livers from
Gcgr/ mice, anti-GCGR-treated mice, and glucagon-treated
primary hepatocytes. Glucose is also an obvious candidate for
a circulating factor that could regulate a-cell mass, perhaps
with low glucose triggering a-cell proliferation. However, while
blood glucose levels are lower in Gcgr/ mice, anti-GCGR trig-
gers a-cell hyperplasia in diabetic mice, even when glucose
levels were above normal.
Our data pointed to amino acids as factors that promote a-cell
hyperplasia when hepatic glucagon signaling is inhibited. As
amino acids are substrates for glucagon-regulated metabolism
in the liver (Morris, 2002), their role as sensors of glucagon
signaling provides a satisfying mechanism for how a-cells are
informed about the degree of glucagon signaling in the liver.
When hepatic glucagon signaling is sufficient to activate amino
acid catabolism, serum amino acid levels are low, and a-cellnt Hepatic Amino Acid Metabolism
lls (C) inGcgr/ andGcgr+/+mice. Average number of islets counted per group
as 100–600. Data are mean ± SEM; n = 3–4 mice per time point. *p% 0.05.
. Data are mean ± SEM; n = 7–9 mice per time point.
. *p = 0.01. Wt, wild-type.
re mean ± SEM.
/+ mice. TfR, transferrin receptor.
SEM; n = 3–14 mice per time point. *p = 0.01.
ata are mean ± SEM; n = 10 mice per time point.
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F
G
Figure 5. Anti-GCGR and Amino Acids Promote a-Cell Replication In Vivo and Ex Vivo
(A) Schematic of lineage-tracing experimental design. IV inject, intravenous injection; IP inject, intraperitoneal injection; IgG, immunoglobulin G.
(B) Immunofluorescent (IF) staining for insulin and tdTomato (top)and forglucagonandtdTomato (bottom) in islets fromGcgCreERT2;tdTomato reportermice14days
after treatment with anti-GCGR (10 mg/kg, qw). Images are representative of 4–6 mice per group. Insets in panels show hormone-only staining. Scale bars, 50 mm.
(C) IF staining for glucagon and ki67 in islets fromGcgCreERT2;tdTomatomice, as in (A). Two individual islets, representative of islets from 4–6mice per group are
shown. Scale bars, 50 mm.
(D) Quantification of a-cell-specific ki67 staining of islets in (C). Ctrl, control.
(E) Schematic of ex vivo islet pulse-chase experiment.
(F) Images of live, isolated islets from C57B6 orGcgCreERT2;tdTomatomice 24 hr after incubation with 4-OH-tamoxifen (Tam) in vitro. Wt, wild-type. Scale bars,
400 mm.
(G) Quantification by FACS of tdTomato-positive (tdTomato +ve) a-cells in islets isolated from GcgCreERT2;tdTomato mice cultured in low or high amino acids
(AA) for 7 days. Data are paired between islets from the same mouse. *p% 0.001.
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Figure 6. mTOR Activation in a-Cells Is Required for Anti-GCGR Induction of a-Cell Hyperplasia
(A) IF staining for pS6 and glucagon in islets of neonatal Gcgr+/+ and Gcgr/ mice. Arrows indicate co-stained cells. Data are representative of n = 6 mice per
group. Scale bars, 50 mm.
(B) IF staining for pS6 and glucagon in islets of C57B6 mice treated with anti-GCGR (10 mg/kg) ± rapamycin (rapa; 10 mg/kg; dosing every 3 days [q3d]) for
12 days. Data are representative of n = 6 mice per group. veh, vehicle. Scale bars, 50 mm.
(C and D) a-cell (C, left) and b-cell (C, right) area/islet area and serum glucagon (D) in mice co-treated with anti-GCGR and rapamycin, as in (B). Ctrl, control; IgG,
immunoglobulin G. Data are mean ± SEM; n = 6. *p% 0.05; ns, not significant.
(legend continued on next page)
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mass remains at steady-state levels. When hepatic glucagon
signaling is low or absent, as in neonatal (Figure 4), Gcg/
(Watanabe et al., 2012), Gcgr/, and anti-GCGR-treated mice,
amino acid catabolism is inactive, and serum amino acids are
high (Figures 2 and 3) and may promote a-cell replication
(Figure 5). As serum amino acids increase to higher levels in
anti-GCGR-treated mice on a high-protein diet, compared to
the levels in mice on an isocaloric, low-protein diet (Figure S6),
it is likely that the amino acids come from the catabolism of die-
tary protein in tissues other than the liver and accumulate in the
serum due to the inability of the liver to clear them in the absence
of glucagon signaling. We suggest that the requirement for
mTOR activation in anti-GCGR-stimulated a-cell proliferation
and maintenance of a-cells in Gcgr/ mice links the physiolog-
ical mechanism of a liver to an islet metabolic circuit controlling
a-cell mass with the molecular sensing of glucagon signaling in
the liver and activation of a proliferative pathway in the a-cell.
In this circuit, amino acids act as both hepatic sensors and
a-cell activators. Multiple amino acids act as anaplerotic sources
of metabolites for cell growth (Csibi et al., 2013; Amelio et al.,
2014), and more than one amino acid is required to activate
mTOR in vitro. For example, leucine activation of mTOR requires
glutamine (Nicklin et al., 2009). It is, therefore, likely that multiple
amino acids drive a-cell hyperplasia in anti-GCGR-treated mice.
Mimicking the degree of the anti-GCGR-induced increase in
serum amino acids by administering amino acid cocktails
directly to mice is difficult to achieve for a sufficient period of
time to induce a-cell proliferation. This is, in part, due to the
homeostatic nature of the system under study, in which admin-
istration of amino acids promotes glucagon secretion, which,
in turn, promotes clearance by the liver and reduces serum levels
back to normal. Future work will address the interesting question
about the precise role that each amino acid plays in a-cell
proliferation.
Hepatic gluconeogenesis is particularly important for survival
in newborns. In mice, mTOR regulates neonatal autophagy,
which provides amino acid substrates for gluconeogenesis
(Efeyan et al., 2013). Mice defective in the activation of gluco-
neogenesis (Boj et al., 2012) or with a constitutively active
mTOR pathway that prevents autophagy (Efeyan et al., 2013)
die soon after birth. However, Gcgr/ mice have normal post-
natal blood glucose levels and survive the postnatal period
without difficulty, suggesting that glucagon is not required for
the activation of the hepatic gluconeogenesis at birth. In sup-
port of this, we found that gluconeogenic genes were increased
after birth independently of glucagon (Figure S5D). Furthermore,
in Gcgr+/+ mice, glucagon did not activate amino acid catabo-
lism or urea cycle genes until about 7 days after birth. As a
result, serum amino acids were high shortly after birth in both
Gcgr+/+ and Gcgr/ mice. Therefore, while glucagon may
play a role in postnatal, hepatic maturation, its ability to regulate
gluconeogenic gene expression and to activate amino acid(E) Serum amino acid levels in mice co-treated anti-GCGR (10 mg/kg) ± rapamyc
(F and G) IF co-staining of pS6 and glucagon (F) and of EdU and glucagon (G) in is
levels ± rapamycin (0.01 ng/ml) for 7 days. Two islets, representative of 10- to 28
(H) Quantification of the total number of EdU-positive (Edu+ve) cells (top) and EdU
low or high amino acid levels for 7 days. Data are mean ± SEM.
506 Cell Reports 12, 495–510, July 21, 2015 ª2015 The Authorscatabolism is delayed. Perhaps this allows for the sparing of
amino acids for conversion to glucose, liver protein biosyn-
thesis, and organ growth until sufficient nutrient intake from
the mother is established. The mechanism for this delay is un-
clear but is not attributable to low serum glucagon or a lack of
GCGR expression at birth.
A role for hepaticmetabolism in the postnatal regulation of islet
cell development has not been described previously. This study
highlights a likely role for amino acids in a liver-to-islet metabolic
circuit in establishing a-cell mass. In particular, as serum amino
acid levels fell in Gcgr+/+ mice throughout the postnatal period,
a-cells stopped proliferating. In addition, we observed a dra-
matic reduction in a-cell mass in Gcgr+/+ mice after P19, which
did not occur in Gcgr/ mice. However, this could be triggered
either by reducing serum amino acids through re-activation of
amino acid catabolism in the liver or by rapamycin-mediated
inhibition of a-cell mTOR activity. Together, this lack of a-cell
pruning after weaning and the delay in switching off mTOR-
dependent a-cell proliferation in Gcgr/ mice led to an almost
20-fold increase in a-cell mass at 3 months of age. Notably,
mutations in the mTOR pathway have been found in human
glucagonomas (Jiao et al., 2011); rapamycin was found to inhibit
alphaTC1 cell proliferation in vitro (Liu et al., 2011); and
Everolimus, an mTOR inhibitor, was recently approved for
the treatment of human pancreatic neuroendocrine tumors,
including glucagonomas.
Using an inducible a-cell-lineage tracing mouse model, we
conclusively demonstrated that the extra a-cells in islets after
anti-GCGR treatment were derived through replication of the
pre-labeled a-cells in situ. In addition, using a neurogenin-3
(Ngn3) endocrine precursor-lineage tracing mouse, we found
that Ngn3-positive precursors did not contribute to the a-cell
pool after anti-GCGR treatment. This was surprising, as in the
Pax4-driven model of a-cell depletion, neurogenin-3 (Ngn3)-
derived cells were a major source of new a-cells (Al-Hasani
et al., 2013). In one respect, a-cell depletion driven by Pax4
expression is similar to anti-GCGR treatment in that both create
a deficiency in hepatic glucagon signaling. However, in contrast
to anti-GCGR treatment, islets in the Pax4-driven model are
always depleted of a-cells and, therefore, have no circulating
glucagon-derived peptides or other a-cell-derived factors that
could potentially inhibit Ngn3+ve precursors when a-cells are
present.
The mechanisms regulating the conversion of a-cells into
b-cells are unknown. Glucagon and insulin co-expressing/bi-
hormonal cells may have the potential to undergo a- to b-cell
transdifferentiation and may represent an intermediate cell in a
b-cell regeneration pathway (Thorel et al., 2010; Chung et al.,
2010; Al-Hasani et al., 2013). Anti-GCGR treatment increased
the number of this normally rare population of bi-hormonal cells
in db/db diabetic mice, but the contribution of these cells to
glucose homeostasis in the presence of anti-GCGR and theirin (10 mg/kg; q3d) for 12 days. Data are mean ± SEM; n = 5–6 mice per group.
olated mouse islets incubated in media containing low or high amino acid (AA)
-islet sections per group are shown. Scale bars, 100 mm.
-positive a-cells (bottom) in isolatedmouse islets incubated inmedia containing
Figure 7. mTOR Activity in a-Cells Is Required for Maintenance of a-Cell Mass
(A) IF staining for pS6 and glucagon in islets of Gcgr/ mice (top), Gcgr/ mice treated with rapamycin (10 mg/kg; q3d) for 12 days (middle) or Gcgr/ mice
9 days after expression of GCGR in the liver using adenovirus (Ad-GCGR) (bottom). Scale bars, 50 mm.
(legend continued on next page)
Cell Reports 12, 495–510, July 21, 2015 ª2015 The Authors 507
ultimate fate in db/db mice are difficult to determine. Bi-hor-
monal cells also increase in non-diabetic mice treated with
anti-GCGR, but, similar to Gcgr/ mice, tdTomato-positive
a-cells accumulate without significant conversion into non-
glucagon-expressing b-like cells. We were, therefore, surprised
to find that once mTOR activity in a-cells was blocked in
GlcCreERt2;tdTomato;Gcgr/ mice, there was a dramatic in-
crease in the number of glucagon-negative, insulin-positive,
tdTomato-positive cells in the islets of these mice. These data
demonstrate that, at least in non-diabetic mice with excess
a-cells, mTOR prevented a- to b-cell transdifferentiation, and
once this block was removed, some a-cells were competent to
transdifferentiate into b-like cells. It is, therefore, possible that
a-cells in Gcgr/ mice may represent a mixture of molecularly
distinct lineages, differing in their potential to adopt different
cell fates. Consistent with this, we detected pS6 in many, but
not all, a-cells in Gcgr/ mice. Finally, the molecular machinery
that enables a-cells, but not b-cells, to activate mTOR and pro-
liferate in response to amino acids remains unknown. Future
studies focusing on the molecular identity of a-cells will provide
further details on the mechanisms determining a-cell fate. These
studies will help determine the potential for a safe and effective
treatment of diabetes with regulators of hepatic glucagon
signaling or a-cell function that can provide both acute control
of hyperglycemia and long-term improvement of diabetes
through transdifferentiation of a-cells into b-cells.EXPERIMENTAL PROCEDURES
Animal Models
Gcgr/ mice were generated from targeted embryonic stem (ES) cells
(KOMP; Project ID VG12492) in which the lacZ gene replaces the first exon
of Gcgr. To generate the GcgCreERT2 transgenic mouse, a BAC transgene
spanning 100 kb of theGcg locus was generated by replacing the ATG and first
coding exon ofGcgwith a cDNA encoding a tamoxifen-inducible Cre-estrogen
receptor fusion protein.GcgCreERT2;tdTomato reporter mice were generated
by intercrosses with mice carrying an inducible loxP-STOP-loxP tdTomato
gene targeted to the ROSA26 locus, and Ngn3Cre mice (Gu et al., 2002)
were used to generate Ngn3Cre:tdTomato reporter mice in a similar manner.
For the induction of GcgCreERT2;tdTomato or Ngn3CreER;tdTomato trans-
genic alleles, tamoxifen (Sigma-Aldrich, #T5648) in corn oil (40 mg/ml) was
administered at 200 mg/kg every other day for 2 weeks by intraperitoneal
(i.p.) injection or oral gavage.
Neonatal mice were aged based on plug dates using timed pregnancies.
Adenoviruses expressing human GCGR or GFP (Vector Biolabs) were given
by intravenous (i.v.) tail vein injection. Anti-GCGR was administered by i.v. or
i.p injection at doses and frequencies indicated in the figure legends. Rapamy-
cin was administered by i.p. injection at 10 mg/kg, every 3 days.
The Genentech Institutional Animal Care and Use Committee approved all
animal studies.(B and C) a-cell and b-cell area/islet (B) and serum glucagon levels (C), inGcgr/
± SEM; n = 5–6 mice per group. *p% 0.01; ns, not significant. veh, vehicle; Pre,
(D) IF staining for tdTomato and glucagon in a-cells (top) and tdTomato
CreERT2;tdTomato;Gcgr/mice treated with rapamycin (10 mg/kg; q3d) for 12 d
with rapamycin, as in Figure 5A. Arrows show tdTomato/insulin-positive, glucago
(E) IF staining for activated caspase3 and glucagon in islets fromGcgr/mice tre
caspase3/glucagon double-positive cells. Scale bars, 50 mm.
(F) IF staining for Nkx6.1 (left), Glut2 (center), or C-peptide (right) with glucagon a
rapamycin (10 mg/kg; q3d) for 12 days. White arrows show b-cell-marker-pos
marker-positive, tdTomato-positive, glucagon-positive cells.
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Blood glucose levels of blood drawn from the tail vein were measured using a
OneTouch Ultra glucometer. Glucose tolerance tests after an overnight fast
were performed as described previously (Mukund et al., 2013). Serum
glucagon levels were measured using an ELISA (Meso Scale Discovery).
Metabolomics was performed using gas chromatography time-of-flight
mass spectrometry (GCTOF MS) as described previously (Fiehn and Kind,
2007). Individual amino acids were quantified by gas chromatography/mass
spectrometry (GC-MS).
Immunofluorescence and Histomorphometry
Immunostaining was performed on 5- to 7-mm formalin-fixed, paraffin-
embedded (FFPE) sections using citrate-buffered boiling epitope retrieval.
The following antibodies were used: guinea pig anti-Insulin (Abcam, #7842);
mouse anti-Glucagon (Sigma-Aldrich, #G2654); rabbit anti-pS6 (Cell Signaling
Technology, #4858) in combination with TSA (tyramide signal amplification)
(Invitrogen, #T20936); rabbit anti-RFP (Rockland, #600-401-379); and appro-
priate Alexa Fluor 488-, 555-, 594-, or 647-labeled secondary antibodies
(Invitrogen). Nuclei were stained with Hoechst 33342 (Life Technologies,
#H21492). Immunofluorescence was quantified from images of pancreatic
sections using MATLAB software (version R2012b, Mathworks).
In Vitro Islet Culture and a-Cell FACS
Tissue culture plates were coated with Matrigel (BD Biosciences, #354262),
diluted 1:3 in RPMI 1640. RPMI 1640 lacking phenol red, amino acids, and
glucose was supplemented with 11 mM glucose, 10% fetal bovine serum
(FBS), 1 mM 4-OHT (Sigma-Aldrich, #H6278), and 13 penicillin/streptomycin
(pen/strep), and amino acids were as described in Supplemental Experimental
Procedures. Paired biological replicates (30–40 islets each) were cultured for
7 days, treated with 1 ml dispase (BD Biosciences, #354235) for 2 min at
37C, and washed and prepared for FACS. Islet pictures were captured using
an EVOS FL Imaging System. Human islets isolated from lean individualswith a
hemoglobin A1c (HbA1c) score <5 were obtained from ProdoLabs.
Statistical Analyses
Non-parametric t tests were performed in GraphPad Prism 6 as stated in the
figure legends.
A p value <0.05 was considered statistically significant.
ACCESSION NUMBERS
The accession number for microarray data is GEO: GSE68145.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.06.034.
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